CHMP of­fers pos­i­tive opin­ion for two high-pro­file drugs as part of lat­est batch of rec­om­men­da­tions

When it comes to the Eu­ro­pean Med­i­cines Agency’s drug re­view com­mit­tee, known as CHMP, any pos­i­tive opin­ions it gives to a drug are all but cer­tain to be ap­proved across the EU. And the com­mit­tee just doled out opin­ions to a batch of 10 drugs, in­clud­ing two with high­er pro­files.

The Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use, aka CHMP, rec­om­mend­ed sev­en brand-name drugs and three gener­ic — for mar­ket­ing au­tho­riza­tion in the EU. And while the Eu­ro­pean Com­mis­sion has to sign off be­fore those drugs go to mar­ket, it’s rare that the com­mis­sion bucks the com­mit­tee’s choic­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER